Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Abstract

The envelope spike (S) proteins of MERS-CoV and SARS-CoV determine the virus host tropism and entry into host cells, and constitute a promising target for the development of prophylactics and therapeutics. Here, we present high-resolution structures of the trimeric MERS-CoV and SARS-CoV S proteins in its pre-fusion conformation by single particle cryo-electron microscopy. The overall structures resemble that from other coronaviruses including HKU1, MHV and NL63 reported recently, with the exception of the receptor binding domain (RBD). We captured two states of the RBD with receptor binding region either buried (lying state) or exposed (standing state), demonstrating an inherently flexible RBD readily recognized by the receptor. Further sequence conservation analysis of six human-infecting coronaviruses revealed that the fusion peptide, HR1 region and the central helix are potential targets for eliciting broadly neutralizing antibodies.

References 50

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.
    Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing · 2012

    No notice
12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.
    Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core · 2004

    No notice
17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

25. 25.
    Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions · 2015

    No notice
26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

28. 28.
    RELION: Implementation of a Bayesian approach to cryo-EM structure determination · 2012

    No notice
29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

32. 32.
    Features and development of Coot · 2010

    No notice
33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 33

• PEDV: Insights and Advances into Types, Function, Structure, and Receptor Recognition · 2022
  No notice
• Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape · 2022
  No notice
• SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome · 2021
  No notice
• Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry · 2021
  No notice
• Broad betacoronavirus neutralization by a stem helix–specific human antibody · 2021
  No notice
• Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design · 2021
  No notice
• N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2 · 2021
  No notice
• Different Cases of SARS-CoV-2 Infection and Its Impact on Health and Economy with Special Emphasis on Antiviral Drug Targets · 2020
  Not checked
• Modulation of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in receptor, innate immunity and drug antiviral candidate · 2020
  Not checked
• Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses · 2020
  No notice
• Cell entry mechanisms of SARS-CoV-2 · 2020
  No notice
• The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens · 2020
  No notice
• Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein · 2020
  No notice
• The ACE2 expression in Sertoli cells and germ cells may cause male reproductive disorder after SARS‐CoV‐2 infection · 2020
  No notice
• Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition · 2020
  No notice
• Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein · 2020
  No notice
• FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2 · 2020
  No notice
• SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity · 2020
  No notice
• Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein · 2020
  No notice
• A human monoclonal antibody blocking SARS-CoV-2 infection · 2020
  Corrected

and 13 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.